Blood Pressure Treatment Through Vaccine-How it works
How much better would life be for a hypertensive person if you could simply have a vaccination for high blood pressure and do away with the nuisance of your daily tablets?
In a trial which was carried out earlier this year a group of 72 people (65 men and 7 women with an average age of 51 years 6 months) who were suffering from mild or moderate hypertension were injected with a low dose (100 micrograms) vaccine, a high dose (300 micrograms) vaccine or a placebo. This process was then repeated after four weeks and at the end of three months.
Two weeks after the final injection it was found that the people given the high dose vaccine were showing a fall in excess of 5 mm Hg in their systolic blood pressure and nearly 3 mm Hg in their diastolic blood pressure.
Possible more significant, it was also found that the usual, and possibly dangerous, spike in blood pressure that happens in the early morning between 5 am and 8 am was also down considerably by 25 mm Hg systolic and 13 mm Hg diastolic.
The trial patients all tolerated the vaccine without problem and there were no safety issues during the trial.
The trial vaccine, which is called CYT006-ANgQb, is designed to work in the same way as the existing drugs and so may clearly be an alternative for those people whose high blood pressure is now controlled using ACE inhibitors or AT-2 receptor blockers.
So what about those people whose blood pressure is currently being controlled with the alternatives of beta blockers (such as Sectral, Kerlone, Blocadren, Ziac, Tenormin, Toprol XL, Betapace, Lopressor and Zebeta) or calcium channel blockers (such as Norvasc, Cardizem, Calan, Sular, Tiazac, Vascor, Lotrel, Adalat, Procardia and Verelan)?
Of course, it is early days yet and further trials will be necessary before we see a vaccine in everyday use for the treatment of high blood pressure. However, if the researchers are correct, it seems likely that this vaccine is going to be effective for a lot of sufferers, whatever the treatment currently being given.
Naturally time will tell, but this is clearly an extremely encouraging development.